Hepatitis C testing and infection rates in bipolar patients with and without comorbid substance use disorders

Annette Matthews, Marilyn Huckans, Aaron D. Blackwell, Peter Hauser

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Objectives: To determine and compare hepatitis C (HCV) screening and testing rates among four groups: those with (i) bipolar disorder [BD group (history of BD but no substance use disorder)]; (ii) substance use disorders [SUD group (history of SUD but no BD)]; (iii) co-occurring disorders [DD group (history of both BD and an SUD)]; and (iv) a control group (no history of either bipolar disorder or substance use disorder). Our hypothesis was that HCV antibody testing rates and HCV prevalence would be higher in the BD, SUD, and DD groups than the control group. Methods: Data were retrospectively collected on 325,410 patients seen between 1998 and 2004 within facilities and clinics of the Veterans Integrated Service Network (VISN) 20 Northwest Veterans Health Care Administration from electronic medical records. HCV screening and prevalence rates were compared between the BD, SUD, DD, and control groups. Odds ratios and relative risks were determined and compared between groups. Results: Patients in the BD, SUD, and DD groups had been tested at a higher rate than controls and were at increased risk for HCV infection compared with controls. These high-risk groups had a 1.31-fold, 4.86-fold, and 5.46-fold increase in the relative risk of HCV infection, respectively. Overall, compared to the control group, the relative risk of a patient having HCV if he or she had BD (with or without an SUD) was 3.6. Conclusions: Patients with BD and comorbid SUD had an over fourfold increase in relative risk for HCV than our control group and a similar risk as patients in our SUD group. Furthermore, even if bipolar patients did not have a comorbid SUD (the BD group), their relative risk of HCV was significantly higher than that of the control group. This suggests that patients with BD, particularly those with a comorbid SUD, should be screened and tested for HCV.

Original languageEnglish (US)
Pages (from-to)266-270
Number of pages5
JournalBipolar Disorders
Volume10
Issue number2
DOIs
StatePublished - Mar 2008

Fingerprint

Hepatitis C
Substance-Related Disorders
Infection
Control Groups
Bipolar Disorder
Veterans Health
Hepatitis C Antibodies
Electronic Health Records
Veterans
Odds Ratio
Delivery of Health Care

Keywords

  • Bipolar disorder
  • Comorbidity
  • Epidemiology
  • Hepatitis C
  • Interferon
  • Mental health
  • Mood disorders
  • Substanceuse disorders
  • United States Department of Veterans Affairs

ASJC Scopus subject areas

  • Neuroscience(all)
  • Neuropsychology and Physiological Psychology

Cite this

Hepatitis C testing and infection rates in bipolar patients with and without comorbid substance use disorders. / Matthews, Annette; Huckans, Marilyn; Blackwell, Aaron D.; Hauser, Peter.

In: Bipolar Disorders, Vol. 10, No. 2, 03.2008, p. 266-270.

Research output: Contribution to journalArticle

Matthews, Annette ; Huckans, Marilyn ; Blackwell, Aaron D. ; Hauser, Peter. / Hepatitis C testing and infection rates in bipolar patients with and without comorbid substance use disorders. In: Bipolar Disorders. 2008 ; Vol. 10, No. 2. pp. 266-270.
@article{6b82733449ec45459441dd5dedeb9732,
title = "Hepatitis C testing and infection rates in bipolar patients with and without comorbid substance use disorders",
abstract = "Objectives: To determine and compare hepatitis C (HCV) screening and testing rates among four groups: those with (i) bipolar disorder [BD group (history of BD but no substance use disorder)]; (ii) substance use disorders [SUD group (history of SUD but no BD)]; (iii) co-occurring disorders [DD group (history of both BD and an SUD)]; and (iv) a control group (no history of either bipolar disorder or substance use disorder). Our hypothesis was that HCV antibody testing rates and HCV prevalence would be higher in the BD, SUD, and DD groups than the control group. Methods: Data were retrospectively collected on 325,410 patients seen between 1998 and 2004 within facilities and clinics of the Veterans Integrated Service Network (VISN) 20 Northwest Veterans Health Care Administration from electronic medical records. HCV screening and prevalence rates were compared between the BD, SUD, DD, and control groups. Odds ratios and relative risks were determined and compared between groups. Results: Patients in the BD, SUD, and DD groups had been tested at a higher rate than controls and were at increased risk for HCV infection compared with controls. These high-risk groups had a 1.31-fold, 4.86-fold, and 5.46-fold increase in the relative risk of HCV infection, respectively. Overall, compared to the control group, the relative risk of a patient having HCV if he or she had BD (with or without an SUD) was 3.6. Conclusions: Patients with BD and comorbid SUD had an over fourfold increase in relative risk for HCV than our control group and a similar risk as patients in our SUD group. Furthermore, even if bipolar patients did not have a comorbid SUD (the BD group), their relative risk of HCV was significantly higher than that of the control group. This suggests that patients with BD, particularly those with a comorbid SUD, should be screened and tested for HCV.",
keywords = "Bipolar disorder, Comorbidity, Epidemiology, Hepatitis C, Interferon, Mental health, Mood disorders, Substanceuse disorders, United States Department of Veterans Affairs",
author = "Annette Matthews and Marilyn Huckans and Blackwell, {Aaron D.} and Peter Hauser",
year = "2008",
month = "3",
doi = "10.1111/j.1399-5618.2007.00472.x",
language = "English (US)",
volume = "10",
pages = "266--270",
journal = "Bipolar Disorders",
issn = "1398-5647",
publisher = "Blackwell Munksgaard",
number = "2",

}

TY - JOUR

T1 - Hepatitis C testing and infection rates in bipolar patients with and without comorbid substance use disorders

AU - Matthews, Annette

AU - Huckans, Marilyn

AU - Blackwell, Aaron D.

AU - Hauser, Peter

PY - 2008/3

Y1 - 2008/3

N2 - Objectives: To determine and compare hepatitis C (HCV) screening and testing rates among four groups: those with (i) bipolar disorder [BD group (history of BD but no substance use disorder)]; (ii) substance use disorders [SUD group (history of SUD but no BD)]; (iii) co-occurring disorders [DD group (history of both BD and an SUD)]; and (iv) a control group (no history of either bipolar disorder or substance use disorder). Our hypothesis was that HCV antibody testing rates and HCV prevalence would be higher in the BD, SUD, and DD groups than the control group. Methods: Data were retrospectively collected on 325,410 patients seen between 1998 and 2004 within facilities and clinics of the Veterans Integrated Service Network (VISN) 20 Northwest Veterans Health Care Administration from electronic medical records. HCV screening and prevalence rates were compared between the BD, SUD, DD, and control groups. Odds ratios and relative risks were determined and compared between groups. Results: Patients in the BD, SUD, and DD groups had been tested at a higher rate than controls and were at increased risk for HCV infection compared with controls. These high-risk groups had a 1.31-fold, 4.86-fold, and 5.46-fold increase in the relative risk of HCV infection, respectively. Overall, compared to the control group, the relative risk of a patient having HCV if he or she had BD (with or without an SUD) was 3.6. Conclusions: Patients with BD and comorbid SUD had an over fourfold increase in relative risk for HCV than our control group and a similar risk as patients in our SUD group. Furthermore, even if bipolar patients did not have a comorbid SUD (the BD group), their relative risk of HCV was significantly higher than that of the control group. This suggests that patients with BD, particularly those with a comorbid SUD, should be screened and tested for HCV.

AB - Objectives: To determine and compare hepatitis C (HCV) screening and testing rates among four groups: those with (i) bipolar disorder [BD group (history of BD but no substance use disorder)]; (ii) substance use disorders [SUD group (history of SUD but no BD)]; (iii) co-occurring disorders [DD group (history of both BD and an SUD)]; and (iv) a control group (no history of either bipolar disorder or substance use disorder). Our hypothesis was that HCV antibody testing rates and HCV prevalence would be higher in the BD, SUD, and DD groups than the control group. Methods: Data were retrospectively collected on 325,410 patients seen between 1998 and 2004 within facilities and clinics of the Veterans Integrated Service Network (VISN) 20 Northwest Veterans Health Care Administration from electronic medical records. HCV screening and prevalence rates were compared between the BD, SUD, DD, and control groups. Odds ratios and relative risks were determined and compared between groups. Results: Patients in the BD, SUD, and DD groups had been tested at a higher rate than controls and were at increased risk for HCV infection compared with controls. These high-risk groups had a 1.31-fold, 4.86-fold, and 5.46-fold increase in the relative risk of HCV infection, respectively. Overall, compared to the control group, the relative risk of a patient having HCV if he or she had BD (with or without an SUD) was 3.6. Conclusions: Patients with BD and comorbid SUD had an over fourfold increase in relative risk for HCV than our control group and a similar risk as patients in our SUD group. Furthermore, even if bipolar patients did not have a comorbid SUD (the BD group), their relative risk of HCV was significantly higher than that of the control group. This suggests that patients with BD, particularly those with a comorbid SUD, should be screened and tested for HCV.

KW - Bipolar disorder

KW - Comorbidity

KW - Epidemiology

KW - Hepatitis C

KW - Interferon

KW - Mental health

KW - Mood disorders

KW - Substanceuse disorders

KW - United States Department of Veterans Affairs

UR - http://www.scopus.com/inward/record.url?scp=43149100778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43149100778&partnerID=8YFLogxK

U2 - 10.1111/j.1399-5618.2007.00472.x

DO - 10.1111/j.1399-5618.2007.00472.x

M3 - Article

VL - 10

SP - 266

EP - 270

JO - Bipolar Disorders

JF - Bipolar Disorders

SN - 1398-5647

IS - 2

ER -